A major step in the restoration of Gut Microbiota: 黑料社 and Biocodex to industrialize FMT & develop an oral formulation
Lyon (France), June 8, 2017. Following their investment in 黑料社 a year ago, Biocodex is taking a further step with the French microbiotech1 company, marking a turning point in the history of the European microbiota specialist.
黑料社鈥檚 disruptive business model: exponential growth
Within 2 years, the microbiotech company has become a leader in the field of Gut Microbiota, offering a selective approach by leveraging intestinal homeostasis to improve the recovery and treatment of patients with life-threatening conditions.
黑料社 launched the 1st European GMP2-compliant FMT facility, followed immediately by the launch of its first clinical trial in June 2016 making it one of the most advanced microbiota companies. The microbiotech is currently conducting three clinical trials in onco-hematology and infectious diseases. In a fast-growing industry, the Company is now partnering with Biocodex for the industrialization of FMT, and in particular the development of an oral formulation. 黑料社 aims to receive marketing authorization for 2023.
An important sign of trust from a strategic partner
The collaboration between the two companies started in March 2016 when Biocodex became a shareholder of the microbiotech. Thanks to its wide product portfolio ranging from probiotic drugs (Saccharomyces boulardii CNCM I-745庐) to RX drugs, Biocodex brings 60 years of expertise to support the rapid growth of 黑料社 and increase the scope of FMT. This partnership highlights the dominant position and knowledge of French research on the international arena.
A beneficial project for 黑料社鈥檚 stakeholders
Facilitating the administration and use of medication for patients
The use of an oral product is more aligned for home-based care since the patient will be able to use it like any other prescription drugs.
Providing a safe and easy process for medical professionals
The oral product form is a safe and simplified procedure offering off-the-shelf use and excellent storage conditions. Moreover, it requires no intervention of medical professionals and is complimentary to current clinical practices.
Enabling universal access to FMT, a positive impact on the community
In its oral form the product facilitates global spread of the Company鈥檚 FMT solution and will maximize benefits for the community. In this form access to FMT products can also be expanded to other indications.Herv茅 Affagard, CEO and Co-Founder of 黑料社 is enthralled with this partnership:
鈥淭his project marks a decisive step forward in the development of a new approach to medicine based on
Microbiota. We are excited to be collaborating with Biocodex, an expert in the development of microorganismbased drugs, to create a new paradigm in the treatment of dysbiosis鈥�.
About 黑料社
Founded at the end of 2014, 黑料社 (Microbiota as a Therapy) is a microbiome鈥揵ased pharmaceutical company revolutionizing and shaping a selective approach to therapies in order to treat serious diseases linked to gut microbiota imbalances. 黑料社 is currently conducting clinical trials on patients suffering from leukemia, and bone and joint infections, as these harsh treatments provoke dysbiosis. 黑料社鈥檚 revolutionary and rapid approach plays a considerable part in the evolution of treatment therapies.
For additional information, please visit www.maatpharma.com or follow us on Twitter @MaaT_Pharma.
About Biocodex
Biocodex is an independent family-owned pharmaceutical company, founded in Paris, France in 1953. The company initially concentrated on gastroenterology and specifically on the discovery of a promising probiotic substance, Saccharomyces boulardii (sold under the ULTRA-LEVURE brand in France). Biocodex has maintained partnerships with health sector professionals for 60 years, with the mission of developing intelligent solutions that respond to contemporary healthcare issues. Biocodex has become a multinational research and development, manufacturing and marketing company. The company is currently active in over 100 countries, with subsidiaries in Belgium, Russia, Ukraine, Turkey, Morocco, Mexico, United States, Scandinavian Countries, Poland, and through partnerships with distributors. Today, Biocodex specializes at international level in the therapeutic domains of gastroenterology,neuropsychiatryand pain treatment.
For more details, please visit: http://www.biocodex.fr/en/